NFKB1 and benign prostatic hyperplasia: This signaling paradigm agrees with our data: BPH rats showed high levels of COX-2, TNF-α, and IL-1β, while aescin treatment could attenuate the expression of COX-2 in the prostate through inhibition of the inflammatory-cytokine/NFκB/COX-2 pathway.